Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bausch Health Companies Inc.    BHC   CA0717341071

BAUSCH HEALTH COMPANIES INC.

(BHC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/27/2020 05/28/2020 05/29/2020 06/01/2020 06/02/2020 Date
18.52(c) 18.58(c) 18.48(c) 19.16(c) 18.93(c) Last
5 499 722 7 139 558 6 500 908 6 619 517 6 046 831 Volume
+2.04% +0.32% -0.54% +3.68% -1.20% Change
More quotes
Financials (USD)
Sales 2020 8 041 M - -
Net income 2020 -376 M - -
Net Debt 2020 22 174 M - -
P/E ratio 2020 -18,2x
Yield 2020 -
Sales 2021 8 637 M - -
Net income 2021 -52,8 M - -
Net Debt 2021 20 765 M - -
P/E ratio 2021 -828x
Yield 2021 -
Capitalization 6 717 M 6 717 M -
EV / Sales 2020 3,59x
EV / Sales 2021 3,18x
Nbr of Employees 21 700
Free-Float 99,5%
More Financials
Company
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic... 
Sector
Pharmaceuticals
Calendar
06/10 | 03:50pmPresentation
More about the company
Surperformance© ratings of Bausch Health Companies In
Trading Rating : Investor Rating :
More Ratings
Latest news on BAUSCH HEALTH COMPANIES IN
05/28BAUSCH HEALTH : + Lomb Announces The European Launch Of LuxSmart And LuxGood Pre..
AQ
05/26BAUSCH HEALTH COMPANIES INC. : Entry into a Material Definitive Agreement, Creat..
AQ
05/12BAUSCH HEALTH COMPANIES INC. : Triggering Events That Accelerate or Increase a D..
AQ
05/07BAUSCH HEALTH : Management's Discussion and Analysis of Financial Condition and ..
AQ
05/07BAUSCH HEALTH : Pandemic cuts into Bausch Health sales as company posts US$152-m..
AQ
05/07BAUSCH : 1Q Earnings Snapshot
AQ
05/07Bausch + lomb licenses exclusive rights from stada and xbrane to a biosimilar..
AQ
05/07BAUSCH HEALTH COMPANIES INC. : Results of Operations and Financial Condition (fo..
AQ
05/07BAUSCH HEALTH : and Alfasigma Announce Resolution of XIFAXAN Intellectual Proper..
AQ
05/06Xbrane and STADA partner with Bausch + Lomb for commercialization of Xlucane ..
AQ
05/01BAUSCH HEALTH COMPANIES INC : . - Salix to Highlight New Data across Its Portfol..
AQ
04/30BAUSCH HEALTH : To Participate at 2020 Bank of America Merrill Lynch Global Heal..
AQ
04/30BAUSCH HEALTH : Salix To Highlight New Data Across Its Portfolio Of Products At ..
AQ
04/30BAUSCH HEALTH : Fda approves ortho dermatologics labeling for jublia topical sol..
AQ
04/29BAUSCH HEALTH : Announces 2020 Annual Meeting Of Shareholder Results
AQ
More news
News in other languages on BAUSCH HEALTH COMPANIES IN
05/28BAUSCH HEALTH : + Lomb Announces The European Launch Of LuxSmart And LuxGood Pre..
05/26BAUSCH HEALTH COMPANIES INC. : Entry into a Material Definitive Agreement, Creat..
05/12BAUSCH HEALTH COMPANIES INC. : Triggering Events That Accelerate or Increase a D..
05/07BAUSCH HEALTH : Management's Discussion and Analysis of Financial Condition and ..
05/07BAUSCH HEALTH : Pandemic cuts into Bausch Health sales as company posts US$152-m..
More news
Chart BAUSCH HEALTH COMPANIES INC.
Duration : Period :
Bausch Health Companies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAUSCH HEALTH COMPANIES IN
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 26,45 $
Last Close Price 18,93 $
Spread / Highest target 164%
Spread / Average Target 39,7%
Spread / Lowest Target -36,6%
EPS Revisions
Managers
NameTitle
Joseph C. Papa Chairman & Chief Executive Officer
Paul S. Herendeen Chief Financial Officer & Executive Vice President
Tage Ramakrishna Chief Medical Officer, President-R&D
Robert N. Power Independent Director
David Robert Hale Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAUSCH HEALTH COMPANIES INC.-36.73%6 717
JOHNSON & JOHNSON1.63%387 786
ROCHE HOLDING AG5.96%295 188
MERCK & CO., INC.-11.12%200 817
PFIZER, INC.-7.71%196 974
NOVARTIS AG-9.65%190 248